1. Minimal residual disease in EGFR-mutant non-small-cell lung cancer
   Nathan T. Bain et al, 2022, Frontiers in Oncology CrossRef
2. Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines
   Andrea Cavazzoni et al, 2008, Molecular Cancer Therapeutics CrossRef
3. IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy
   Donatella Romaniello et al, 2023, Frontiers in Cell and Developmental Biology CrossRef